05 / RWE
Rare Disease Evidence
Evidence where the trials are small and the stakes are largest.
Federated real-world data pipelines for orphan indications, combining registries, EHRs, and patient-reported outcomes into decision-grade evidence for development, access, and policy.
[ Overview ]
What we do
for your team.
Rare disease programs need signals from wherever they exist. We connect registries, EHRs, claims and patient communities under a harmonized (OMOP / FHIR) model, with ethical sourcing and consent traceability throughout.
The output is evidence that stands up in front of clinicians, regulators, and payers alike.
BiopharmaPatient AdvocacyPayers
[ Capabilities ]
- Registry & natural history study design
- Cross-registry harmonization (OMOP / FHIR)
- Patient journey and disease progression modeling
- External / synthetic control arm generation
- Patient-reported outcomes and quality-of-life integration
[ Outcomes ]
- 01
Payer-ready evidence for ultra-orphan programs
- 02
Longitudinal outcome models across geographies
- 03
Ethically sourced datasets with full consent traceability